Stock listing
Frankfurt:6GJ Glaukos Corporation Aktie
German listing (Frankfurt) of Glaukos Corporation · home listing NYSE:GKOS
Follow Glaukos Corporation into a list and get an email when it puts out news.
Share price · FWB:6GJ
€214.00 EUR +6.00 (+2.9%)
Close on Nov 20, 2026
- Day range
- €214.00 – €214.00 EURNov 20, 2026
- Market cap
- €12.62B EURAt the close on Nov 20, 2026 · price × 58.98M shares outstanding
- 52-week range
- €81.33 – €218.19 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €3,063 EURMedian day 0 shares · 48 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE:GKOS · Home | $237.31 USD | +4.23 (+1.8%) | 1,089,498 | $238.87 | $244.55 | $233.40 | $233.08 | Close on Nov 20, 2026 |
| Frankfurt:6GJ | €214.00 EUR | +6.00 (+2.9%) | — | €214.00 | €214.00 | €214.00 | €208.00 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:6GJ · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €194.48 | -20.62 | -9.6% | €194.48 | €194.48 | €194.48 | 0 | |
| €215.10 | +9.964 | +4.9% | €215.10 | €215.10 | €215.10 | 7 | |
| €205.14 | -4.821 | -2.3% | €205.14 | €205.14 | €205.14 | 17 | |
| €209.96 | -6.315 | -2.9% | €209.96 | €209.96 | €209.96 | 244 | |
| €216.27 | -1.774 | -0.8% | €216.27 | €216.27 | €216.27 | 20 | |
| €218.05 | +28.73 | +15.2% | €214.95 | €218.19 | €214.28 | 20 | |
| €189.31 | +28.76 | +17.9% | €189.31 | €189.31 | €189.31 | 158 | |
| €160.55 | +3.129 | +2.0% | €160.55 | €160.55 | €160.55 | 240 | |
| €157.43 | -0.132 | -0.1% | €157.43 | €157.43 | €157.43 | 0 | |
| €157.56 | +2.135 | +1.4% | €157.56 | €157.56 | €157.56 | 0 | |
| €155.42 | +2.288 | +1.5% | €155.42 | €155.42 | €155.42 | 112 | |
| €153.13 | +1.582 | +1.0% | €153.13 | €153.13 | €153.13 | 0 | |
| €151.55 | +4.883 | +3.3% | €151.55 | €151.55 | €151.55 | 0 | |
| €146.67 | +1.137 | +0.8% | €146.67 | €146.67 | €146.67 | 0 | |
| €145.53 | +0.841 | +0.6% | €145.53 | €145.53 | €145.53 | 0 | |
| €144.69 | -2.105 | -1.4% | €144.69 | €144.69 | €144.69 | 0 | |
| €146.80 | +0.363 | +0.2% | €146.80 | €146.80 | €146.80 | 0 | |
| €146.43 | -0.803 | -0.5% | €146.43 | €146.43 | €146.43 | 0 | |
| €147.24 | +1.912 | +1.3% | €147.24 | €147.24 | €147.24 | 0 | |
| €145.32 | +4.142 | +2.9% | €145.32 | €145.32 | €145.32 | 0 | |
| €141.18 | -10.30 | -6.8% | €141.18 | €141.18 | €141.18 | 0 | |
| €151.48 | +9.863 | +7.0% | €151.48 | €151.48 | €151.48 | 0 | |
| €141.62 | -3.303 | -2.3% | €141.62 | €141.62 | €141.62 | 0 | |
| €144.92 | +1.057 | +0.7% | €144.92 | €144.92 | €144.92 | 0 | |
| €143.86 | +1.16 | +0.8% | €143.86 | €143.86 | €143.86 | 0 | |
| €142.70 | -0.535 | -0.4% | €142.70 | €142.70 | €142.70 | 0 | |
| €143.24 | +6.18 | +4.5% | €143.24 | €143.24 | €143.24 | 0 | |
| €137.06 | -1.655 | -1.2% | €137.06 | €137.06 | €137.06 | 0 | |
| €138.71 | +5.612 | +4.2% | €138.71 | €138.71 | €138.71 | 0 | |
| €133.10 | -0.63 | -0.5% | €133.10 | €133.10 | €133.10 | 0 | |
| €133.73 | +0.541 | +0.4% | €133.73 | €133.73 | €133.73 | 0 | |
| €133.19 | -4.442 | -3.2% | €133.19 | €133.19 | €133.19 | 0 | |
| €137.63 | -1.671 | -1.2% | €137.63 | €137.63 | €137.63 | 0 | |
| €139.30 | -1.323 | -0.9% | €139.30 | €139.30 | €139.30 | 0 | |
| €140.62 | +1.587 | +1.1% | €140.62 | €140.62 | €140.62 | 0 | |
| €139.04 | -1.864 | -1.3% | €139.04 | €139.04 | €139.04 | 0 | |
| €140.90 | -5.821 | -4.0% | €140.90 | €140.90 | €140.90 | 0 | |
| €146.72 | +0.02 | 0.0% | €146.72 | €146.72 | €146.72 | 0 | |
| €146.70 | +5.133 | +3.6% | €146.70 | €146.70 | €146.70 | 0 | |
| €141.57 | -3.412 | -2.4% | €141.57 | €141.57 | €141.57 | 0 | |
| €144.98 | -7.717 | -5.1% | €144.98 | €144.98 | €144.98 | 0 | |
| €152.70 | -4.224 | -2.7% | €152.70 | €152.70 | €152.70 | 0 | |
| €156.92 | +7.932 | +5.3% | €156.92 | €156.92 | €156.92 | 0 | |
| €148.99 | -1.782 | -1.2% | €149.17 | €149.17 | €148.20 | 160 | |
| €150.77 | -1.43 | -0.9% | €150.77 | €150.77 | €150.77 | 0 | |
| €152.20 | -0.609 | -0.4% | €152.20 | €152.20 | €152.20 | 0 | |
| €152.81 | +3.427 | +2.3% | €152.81 | €152.81 | €152.81 | 0 | |
| €149.38 | -2.497 | -1.6% | €149.38 | €149.38 | €149.38 | 0 | |
| €151.88 | -1.381 | -0.9% | €151.88 | €151.88 | €151.88 | 0 | |
| €153.26 | -1.063 | -0.7% | €153.26 | €153.26 | €153.26 | 0 | |
| €154.33 | +2.004 | +1.3% | €154.33 | €154.33 | €154.33 | 0 | |
| €152.32 | -0.666 | -0.4% | €152.32 | €152.32 | €152.32 | 0 | |
| €152.99 | -3.364 | -2.2% | €152.99 | €152.99 | €152.99 | 0 | |
| €156.35 | +0.765 | +0.5% | €156.35 | €156.35 | €156.35 | 0 | |
| €155.59 | -0.324 | -0.2% | €155.59 | €155.59 | €155.59 | 0 | |
| €155.91 | -3.889 | -2.4% | €155.91 | €155.91 | €155.91 | 0 | |
| €159.80 | +2.814 | +1.8% | €159.80 | €159.80 | €159.80 | 0 |
- Ticker
- Frankfurt:6GJ
- Asset type
- Stock
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 3, 2026
Glaukos Announces Participation in Upcoming Investor Conferences
Latest earnings call · Oct 28, 2026
Glaukos (NYSE:GKOS) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 6, 2026
Investor Presentation (November 2026)
Investor deck · 29 slides
Latest news
Glaukos Announces Participation in Upcoming Investor Conferences
Nov 3, 2026
Closed €209.96 (-2.9%) on Nov 3, 2026
Third Quarter 2026 GAAP to Non-GAAP Recs
Oct 28, 2026
Closed €189.31 (+17.9%) on Oct 29, 2026
Glaukos Announces Third Quarter 2026 Financial Results
Oct 28, 2026
Closed €189.31 (+17.9%) on Oct 29, 2026
Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery
Oct 9, 2026
Closed €141.18 (-6.8%) on Oct 9, 2026
Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases
Oct 8, 2026
Closed €151.48 (+7.0%) on Oct 8, 2026
Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus
Oct 7, 2026
Closed €151.48 (+7.0%) on Oct 8, 2026
Glaukos Announces Second Quarter 2026 Financial Results
Jul 29, 2026
Closed €151.19 (+15.9%) on Jul 30, 2026
Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt
Jul 27, 2026
Closed €133.65 (+0.7%) on Jul 27, 2026
Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29
Jul 8, 2026
Closed €129.83 (+1.7%) on Jul 8, 2026
Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis
Jun 25, 2026
Closed €119.52 (+2.9%) on Jun 25, 2026
Glaukos Corporation on 6ix
- News releases
- 25 in the last 12 months · 43 in all · newest Nov 3, 2026 · oldest 2025
- Calls
- 27 calls with a replay · 27 with a transcript · latest Oct 28, 2026
- Decks
- 68 decks · latest Nov 6, 2026
Where Glaukos Corporation is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE:GKOS · Home listing | NYSE | United States | USD |
| gettex:6GJ | gettex | Germany | EUR |
| LS Exchange:A14VCK | LS Exchange | Germany | EUR |
| Lang & Schwarz:A14VCK | Lang & Schwarz | Germany | EUR |
| BX Swiss:GKOS | BX Swiss | Switzerland | CHF |
| BOATS:GKOS | BOATS | United States | USD |
| Dusseldorf:6GJ | Dusseldorf | Germany | EUR |
| Frankfurt:6GJ · This page | Frankfurt | Germany | EUR |
| Munich:6GJ | Munich | Germany | EUR |
| Stuttgart:6GJ | Stuttgart | Germany | EUR |
| Tradegate:6GJ | Tradegate | Germany | EUR |
| Xetra:6GJ | Xetra | Germany | EUR |
| BMV:GKOS | BMV | Mexico | MXN |
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $13.89B USD
- P/E
- Loss
- EV/sales
- 20.1×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 19.6×
- Gross margin
- 64.8%
- Operating margin
- −25.5%
- Net margin
- −24.6%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.87
Forecasts
9 strong buy · 3 buy · 1 hold · Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.
- Price target
- 242.46 USD · Analysts' mean
- EPS, year to Dec 2026
- 0.64 · 13 analysts
- Revenue, year to Dec 2026
- 780.5M · 14 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Thomas W. Burns | Chairman & Chief Executive Officer |
| Alex R. Thurman | Senior Vice President, Chief Financial Officer |
| Joseph E. Gilliam | President & Chief Operating Officer |
| Paul Bavier | Chief Legal Counsel |
| Robert L. Davis | Senior Vice President, General Counsel & Business Development |
| Chris Lewis | Vice President, Investor Relations & Corporate Affairs |
| Gabriella Szekely | Senior Vice President, Research & Development, Combination Pharmaceutical Products |
| Matt Young | Senior Vice President, Global Operations |
| Michele M. Allegretto | Senior Vice President, Human Resources |
| Tracy M. Founds | Senior Vice President, Global Quality and Medical Safety |
| Jay L. Katz | Chief Medical Officer |
| Tomas Navratil | Chief Development Officer |
Board
| Director | Role |
|---|---|
| Thomas W. Burns | Chairman & Chief Executive Officer |
| Aimee S. Weisner | Director |
| David F. Hoffmeister | Director |
| Denice M. Torres | Director |
| Gilbert H. Kliman | Director |
| Leana S. Wen | Director |
| Marc A. Stapley | Director |
| Mark J. Foley | Lead Independent Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Glaukos (NYSE:GKOS) Q3 2026 Earnings Call | Wed, Oct 28, 2026 · 4:30 PM ET | Replay |
| Glaukos (NYSE:GKOS) Q2 2026 Earnings Call | Wed, Jul 29, 2026 · 4:30 PM ET | Replay |
| Glaukos (NYSE:GKOS) Q1 2026 Earnings Call | Wed, Apr 29, 2026 · 4:30 PM ET | Replay |
| Glaukos (NYSE:GKOS) Q4 2025 Earnings Call | Tue, Feb 17, 2026 · 4:00 PM ET | Replay |
| Glaukos (NYSE:GKOS) Q3 2025 Earnings Call | Wed, Oct 29, 2025 · 4:30 PM ET | Replay |
| Glaukos (NYSE:GKOS) Q2 2025 Earnings Call | Wed, Jul 30, 2025 · 4:30 PM ET | Replay |
| Glaukos (NYSE:GKOS) Q1 2025 Earnings Call | Wed, Apr 30, 2025 · 4:30 PM ET | Replay |
| Glaukos (NYSE:GKOS) Q4 2024 Earnings Call | Thu, Feb 20, 2025 · 4:30 PM ET | Replay |
| Glaukos (NYSE:GKOS) Q3 2024 Earnings Call | Mon, Nov 04, 2024 · 4:30 PM ET | Replay |
| Glaukos (NYSE:GKOS) Q2 2024 Earnings Call | Wed, Jul 31, 2024 · 4:30 PM ET | Replay |
All 27 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 28, 2026 · After close | +33.6% |
| Q2 2026 | Jul 29, 2026 · After close | +4.2% |
| Q1 2026 | Apr 29, 2026 · After close | +22.8% |
| Q4 2025 | Feb 17, 2026 | +10.5% |
| Q3 2025 | Oct 29, 2025 · After close | +13.9% |
| Q2 2025 | Jul 30, 2025 · After close | −8.5% |
| Q1 2025 | Apr 30, 2025 · After close | −11.4% |
| Q4 2024 | Feb 19, 2025 · Before open | +5.0% |
| Q3 2024 | Nov 4, 2024 · After close | −2.7% |
| Q2 2024 | Jul 31, 2024 · After close | +0.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 1, 2024 · After close | +6.2% |
| Q4 2023 | Feb 21, 2024 · After close | −1.4% |
| Q3 2023 | Nov 1, 2023 · After close | −7.6% |
| Q2 2023 | Aug 2, 2023 · After close | −0.4% |
| Q1 2023 | May 3, 2023 · After close | +8.8% |
| Q4 2022 | Feb 22, 2023 · After close | −3.1% |
| Q3 2022 | Nov 2, 2022 · After close | −9.6% |
| Q2 2022 | Aug 3, 2022 · After close | +0.3% |
| Q1 2022 | May 4, 2022 · After close | −5.5% |
| Q4 2021 | Feb 22, 2022 · After close | +3.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 29 slides | Nov 6, 2026 |
| Q3 2026 Earnings Presentation | Earnings | 7 slides | Oct 28, 2026 |
| Investor Presentation (August 2026) | Investor deck | 28 slides | Aug 3, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 27 slides | Jul 29, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 28 slides | Jul 29, 2026 |
| Investor Presentation (May 2026) | Investor deck | 28 slides | May 4, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 31 slides | Apr 29, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 28 slides | Apr 29, 2026 |
| Investor Presentation (March 2026) | Investor deck | 28 slides | Mar 2, 2026 |
| FY2025 Earnings Presentation | Earnings | 13 slides | Feb 17, 2026 |
Show 50 decks
This page holds 50 of 68 decks. Open Decks
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 507.4M | 383.5M | 314.7M | 282.9M | 294.0M | 225.0M | 237.0M | 181.3M | 159.3M | 114.4M |
| Cost of revenue | 111.8M | 94.0M | 75.6M | 69.0M | 66.6M | 91.7M | 38.6M | 25.1M | 21.1M | 16.2M |
| Gross profit | 282.8M | 289.5M | 239.1M | 213.9M | 227.4M | 133.2M | 198.4M | 156.2M | 138.2M | 98.2M |
| Research and development | 150.6M | 136.4M | 138.8M | 123.3M | 101.0M | 85.4M | 68.3M | 49.7M | 38.9M | 29.2M |
| Selling, general and administrative | 331.7M | 261.2M | 224.1M | 192.9M | 179.3M | 171.4M | 176.6M | 119.5M | 96.3M | 64.8M |
| Operating income | -199.6M | -122.4M | -128.7M | -82.3M | -32.9M | -123.6M | -50.3M | -13.0M | -2.28M | 4.24M |
| Depreciation and amortization | 38.1M | 35.6M | 33.7M | 31.6M | 29.7M | 29.4M | 6.31M | 6.26M | 5.48M | 4.72M |
| EBITDA | -161.5M | -86.7M | -95.0M | -50.7M | -3.21M | -94.2M | -44.0M | -6.74M | 3.20M | 8.96M |
| Interest expense | 4.63M | 10.0M | 13.6M | 13.7M | 13.4M | 14.1M | 2.56M | |||
| Income before tax | -193.0M | -145.6M | -133.7M | -98.4M | -49.3M | -132.3M | -50.0M | -12.4M | 1.00K | 4.57M |
| Income tax | -5.35M | 771.0K | 934.0K | 766.0K | 326.0K | -12.0M | -65.5M | 583.0K | 93.0K | 43.0K |
| Net income | -187.7M | -146.4M | -134.7M | -99.2M | -49.6M | -120.3M | 15.4M | -13.0M | -92.0K | 4.52M |
| Earnings per share, basic | -3.28 | -2.77 | -2.78 | -2.09 | -1.07 | -2.70 | 0.41 | -0.37 | 0.00 | 0.14 |
| Earnings per share, diluted | -3.28 | -2.77 | -2.78 | -2.09 | -1.07 | -2.70 | 0.37 | -0.37 | 0.00 | 0.12 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 90.8M | 169.6M | 93.5M | 119.5M | 100.7M | 96.6M | 62.4M | 29.8M | 24.5M | 6.49M |
| Receivables | 108.6M | 60.7M | 39.9M | 36.1M | 33.4M | 36.1M | 38.4M | 18.7M | 16.7M | 14.3M |
| Inventory | 63.6M | 57.7M | 42.0M | 37.8M | 23.0M | 15.8M | 42.6M | 13.3M | 11.2M | 6.84M |
| Current assets | 475.0M | 449.8M | 395.5M | 443.9M | 486.1M | 469.4M | 262.9M | 176.6M | 149.5M | 120.0M |
| Property, plant and equipment | 113.3M | 97.9M | 103.2M | 94.4M | 69.0M | 24.0M | 22.1M | 19.2M | 11.8M | 7.59M |
| Goodwill | 66.7M | 66.1M | 66.1M | 66.1M | 66.1M | 66.1M | 66.1M | |||
| Total assets | 893.5M | 974.8M | 940.4M | 1.00B | 1.05B | 1.01B | 818.4M | 207.0M | 165.8M | 134.4M |
| Accounts payable | 24.6M | 13.0M | 13.4M | 14.4M | 7.33M | 4.37M | 5.78M | 6.29M | 6.24M | 2.97M |
| Current liabilities | 101.3M | 75.1M | 74.0M | 72.4M | 63.4M | 49.7M | 57.7M | 30.4M | 26.8M | 16.9M |
| Total liabilities | 237.3M | 207.8M | 478.6M | 472.4M | 462.5M | 338.1M | 145.1M | 33.1M | 27.6M | 17.1M |
| Shareholders' equity | 656.2M | 766.9M | 461.8M | 530.0M | 587.2M | 667.4M | 673.3M | 173.9M | 138.2M | 117.3M |
| Shares outstanding | 57.5M | 56.4M | 49.1M | 47.8M | 47.0M | 45.2M | 43.5M | 36.1M | 34.6M | 33.9M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -14.8M | -61.3M | -57.8M | -33.1M | 24.7M | -23.0M | -369.0K | 18.9M | 26.1M | 12.3M |
| Capital spending | -7.67M | -6.30M | -20.2M | -30.3M | -47.8M | -6.93M | -4.72M | -10.3M | -6.31M | -6.28M |
| Free cash flow | -22.5M | -67.6M | -78.0M | -63.3M | -23.1M | -29.9M | -5.09M | 8.55M | 19.8M | 6.03M |
| Cash from investing | -77.6M | 47.8M | 14.1M | 44.8M | -58.2M | -205.1M | 43.4M | -26.4M | -12.4M | -26.1M |
| Cash from financing | 11.9M | 91.5M | 15.0M | 6.25M | 39.3M | 262.5M | -9.64M | 21.6M | 4.67M | -1.64M |
| Change in cash | -79.7M | 75.0M | -27.3M | 16.5M | 3.96M | 34.4M | 33.2M | 14.1M | 17.9M | -15.1M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 18, 2026 | Other filings | SEC |
| 4 · Change in ownership | Nov 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 16, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 144 · Notice of proposed sale | Nov 12, 2026 | Other filings | SEC |
| 8-K · Current report | Nov 6, 2026 | Current report | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 30, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Oct 28, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 28, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 28, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 25, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 16, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 28, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 19, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 7, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 3, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | Jul 31, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Jul 29, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 29, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 21, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 16, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 23, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 23, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 23, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 23, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 23, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 23, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 16, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 3, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| SD · Specialized disclosure | May 29, 2026 | ESG report | SEC |
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | May 14, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 11, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 8-K · Current report | May 4, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | May 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 30, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Apr 29, 2026 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 29, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Apr 29, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 29, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 16, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 16, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 16, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 14, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 10, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 25, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 24, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 16, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 2, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Feb 24, 2026 | Offer document | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 10-K · Annual report | Feb 20, 2026 | Annual report | SEC |
| 144 · Notice of proposed sale | Feb 19, 2026 | Other filings | SEC |
| 8-K · Current report | Feb 17, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 11, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 10, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 22, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 22, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 21, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 16, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 13, 2026 | Results | SEC |
| 144 · Notice of proposed sale | Jan 8, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 9, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 26, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 25, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 20, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 18, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 10, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Oct 30, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 29, 2025 | Results | SEC |
| 4 · Change in ownership | Sep 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 22, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 12, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 11, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Aug 20, 2025 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 12, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 12, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 7, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 4, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jul 30, 2025 | Results | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 3, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| SD · Specialized disclosure | May 30, 2025 | ESG report | SEC |
| 4 · Change in ownership | May 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2025 | Insider trade | SEC |
| 8-K · Current report | May 14, 2025 | Current report | SEC |
| 4 · Change in ownership | May 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 9, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 1, 2025 | Quarterly report | SEC |
| 8-K · Current report | Apr 30, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 29, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 23, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 15, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 15, 2025 | Meeting notice | SEC |
This page holds 200 of 1,005 filings. Open Filings
Cap table
Built by 6ix from Glaukos Corporation’s releases · as of Oct 26, 2026
- Common shares
- 59,196,870
- Fully diluted
- 59,196,870
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 59,196,870 | Oct 26, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 26, 2026 | 59,196,870 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Samuel D Isaly Other companies: Synlogic Inc (Director · Aug 28, 2017 – Aug 28, 2017 · Past); Alpine Immune Sciences Inc (Director · Jul 24, 2017 – Jul 24, 2017 · Past); Whitehawk Therapeutics, Inc. (Director · Mar 15, 2017 – Mar 15, 2017 · Past); Nabriva Therapeutics AG (Director · Dec 30, 2016 – Dec 30, 2016 · Past); Roka Bioscience Inc (Director · Sep 21, 2016 – Sep 21, 2016 · Past); Loxo Oncology Inc (Director · Aug 10, 2016 – Dec 8, 2017 · Past); Audentes Therapeutics Inc (Director · Jul 19, 2016 – Jul 19, 2016 · Past); Cartesian Therapeutics, Inc. (Director · Jun 21, 2016 – Jun 27, 2016 · Past); Corvus Pharmaceuticals, Inc. (Director · May 18, 2016 – Jun 23, 2016 · Past); Intellia Therapeutics, Inc. (Director · May 11, 2016 – May 11, 2016 · Past); Adaptimmune Therapeutics PLC (Director · Jan 1, 2016 – Mar 27, 2017 · Past); Otonomy Inc (Director · Nov 17, 2015 – Nov 25, 2015 · Past); Dimension Therapeutics (Director · Oct 27, 2015 – Oct 27, 2015 · Past); Sierra Oncology Inc (Director · Jul 15, 2015 – Jul 21, 2015 · Past); Palvella Therapeutics, Inc. (Director · Jun 29, 2015 – Jul 6, 2015 · Past); Intercept Pharmaceuticals Inc (Director · Apr 9, 2013 – Jul 17, 2015 · Past); Supernus Pharmaceuticals, Inc. (Director · May 4, 2012 – May 4, 2012 · Past); Anthera Pharmaceuticals Inc (Director · May 9, 2011 – Jan 30, 2013 · Past); Amarin Corporation plc (Director · Jan 1, 2011 – Sep 4, 2012 · Past); NxStage Medical Inc (Director · Jul 23, 2008 – Dec 9, 2010 · Past); Albireo Pharma Inc (Director · Feb 12, 2008 – Jun 9, 2009 · Past); Aryx Therapeutics Inc (Director · Nov 7, 2007 – Nov 13, 2007 · Past); Insulet Corporation (Director · May 14, 2007 – May 14, 2007 · Past); Volcano Corp (Director · Jun 14, 2006 – Jun 20, 2006 · Past); Given Imaging Ltd (Director · May 24, 2006 – May 24, 2006 · Past); Avanir Pharmaceuticals Inc (Director · Feb 13, 2006 – May 31, 2006 · Past) | Director · Jun 24, 2015 – Aug 31, 2017 · Past |
| William J. Link Other companies: RxSight, Inc. (Director · Since at least Jul 29, 2021); Tarsus Pharmaceuticals, Inc. (Director · Since at least Oct 15, 2020); LENSAR, Inc. (Director · Since at least Sep 17, 2020); Oyster Point Pharma Inc (Director · Oct 30, 2019 – Jan 5, 2022 · Past); Vivani Medical, Inc. (Director · Nov 18, 2014 – Jun 4, 2019 · Past); Flexion Therapeutics Inc (Director · Sep 10, 2014 – Sep 10, 2014 · Past); Inogen, Inc (Director · Feb 12, 2014 – Feb 20, 2014 · Past); Edwards Lifesciences Corporation (Director · May 15, 2013 – May 8, 2020 · Past) | Director · Jun 24, 2015 – Jun 3, 2021 · Past |
| Denice Torres Other companies: Seaport Therapeutics, Inc. (Board Member · Since at least Apr 30, 2026); Celldex Therapeutics, Inc. (Chief Executive Officer; The Ignited Company · Since at least Jun 5, 2025); 2Seventy Bio Inc (Director · Oct 18, 2021 – May 13, 2025 · Past); Surface Oncology Inc (Director · Jul 6, 2021 – Jun 8, 2022 · Past); Karuna Therapeutics Inc (Director · Dec 22, 2020 – Mar 18, 2024 · Past); Bluebird bio Inc (Director · Aug 10, 2020 – Nov 11, 2021 · Past) | Director · Since at least Mar 1, 2021 |
| Aimee S. Weisner Other companies: LENSAR, Inc. (Director · Since at least Feb 1, 2021); STAAR Surgical Company (Director · Jun 16, 2022 – Jun 20, 2024 · Past); Oyster Point Pharma Inc (Director · Oct 30, 2019 – Jan 3, 2023 · Past); Edwards Lifesciences Corporation (CVP, General Counsel · Jan 14, 2011 – May 9, 2012 · Past); Advanced Medical Optics Inc (EVP, Administration & Sec'y · May 24, 2006 – May 29, 2008 · Past) | Director · Since at least Jun 24, 2015 |
| Gilbert H. Kliman Other companies: Doximity, Inc. (Director · Jun 23, 2021 – Jul 27, 2022 · Past); STAAR Surgical Company (Director · Jun 1, 2020 – Dec 1, 2023 · Past); Venus Concept Inc (Director · Oct 11, 2017 – Nov 7, 2019 · Past); Epocrates Inc (Director · Feb 1, 2011 – Feb 1, 2011 · Past); Intralase Corp (Director · Jan 5, 2006 – Apr 2, 2007 · Past) | Director · Since at least Jun 24, 2015 |
| Jonathan Silverstein Other companies: Arcutis Biotherapeutics, Inc. (Director · Jan 30, 2020 – Oct 2, 2020 · Past); Adicet Bio, Inc. (Director · Jan 25, 2018 – Jun 3, 2020 · Past); Scpharmaceuticals Inc (Director · Nov 16, 2017 – Nov 21, 2017 · Past); Rhythm Pharmaceuticals, Inc. (Director · Oct 4, 2017 – Oct 4, 2017 · Past) | Director · Dec 13, 2017 – Mar 2, 2018 · Past |
| David F. Hoffmeister Other companies: StepStone Group Inc. (Director · Since at least Sep 15, 2020); ICU Medical, Inc. (Independent Director · Since at least Jan 5, 2018); Celanese Corporation (Director · May 2, 2006 – May 9, 2025 · Past) | Director · Since at least Jun 24, 2015 |
| Olav Bergheim Other companies: Sonendo, Inc. (Director · Since at least Oct 28, 2021); Adagio Medical Holdings, Inc (CEO and Chairman, Director · Jul 31, 2024 – Jul 31, 2024 · Past); Volcano Corp (Director · Jun 14, 2006 – Aug 1, 2008 · Past) | Director · Jun 24, 2015 – Jul 23, 2015 · Past |
| Mark J. Foley Other companies: SI-BONE, Inc. (Director · Jun 13, 2019 – Jun 16, 2020 · Past); Revance Therapeutics, Inc. (President & CEO, Director · Nov 7, 2017 – Feb 4, 2025 · Past) | Director · Since at least Dec 13, 2017 |
| Paul S Madera Other companies: Sonendo, Inc. (Director · Oct 28, 2021 – Nov 2, 2021 · Past); ForgeRock Inc (Director · Sep 15, 2021 – Mar 8, 2022 · Past) | Director · Jun 24, 2015 – Jun 30, 2015 · Past |
All 28 people
| Person | Seat |
|---|---|
| Robert More Other companies: Tyra Biosciences, Inc. (Board Member · Since at least Sep 14, 2021); Vir Biotechnology, Inc. (Director · Since at least Oct 10, 2019) | Director · Jun 24, 2015 – Jun 30, 2015 · Past |
| Joseph E. Gilliam Other companies: Caris Life Sciences, Inc. (Board Member · Since at least Jun 17, 2025) | President & Chief Operating Officer · Since at least May 5, 2017 |
| Leana S. Wen Other companies: UroGen Pharma Ltd. (Director · Since at least Sep 8, 2022) | Director · Since at least Mar 1, 2021 |
| Marc A. Stapley Other companies: Veracyte, Inc. (Chief Executive Officer, Director · Since at least Jun 1, 2021) | Director · Since at least May 30, 2019 |
| Thomas W. Burns Other companies: Pulmonx Corporation (Board Member · Since at least Sep 30, 2020) | Chairman & Chief Executive Officer · Since at least Jun 24, 2015 |
| Alex R Thurman | SVP & CHIEF FINANCIAL OFFICER · Since at least Apr 1, 2022 |
| Alex R. Thurman | Senior Vice President, Chief Financial Officer · Since at least Aug 11, 2026 |
| Chris Lewis | Vice President, Investor Relations & Corporate Affairs · Since at least Apr 16, 2026 |
| Chris M Calcaterra | Chief Operating Officer · Jun 24, 2015 – Mar 24, 2022 · Past |
| Gabriella Szekely | Senior Vice President, Research & Development, Combination Pharmaceutical Products · Since at least Nov 4, 2026 |
| Jay L. Katz | Chief Medical Officer · Since at least Nov 4, 2026 |
| Matt Young | Senior Vice President, Global Operations · Since at least Nov 4, 2026 |
| Michele M. Allegretto | Senior Vice President, Human Resources · Since at least Nov 4, 2026 |
| Paul Bavier | Chief Legal Counsel · Since at least Dec 4, 2025 |
| Richard L Harrison | CFO & Treasurer · Jun 24, 2015 – Jan 12, 2017 · Past |
| Robert L. Davis | Senior Vice President, General Counsel & Business Development · Since at least Nov 4, 2026 |
| Tomas Navratil | CHIEF DEVELOPMENT OFFICER · Since at least Apr 1, 2022 |
| Tracy M. Founds | Senior Vice President, Global Quality and Medical Safety · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Glaukos Corporation.